Pre-emptive versus prophylactic use of TKIs after allo-SCT in patients with Philadelphia chromosome-positive ALL

Tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL fusion gene product have...

D-ALBA trial: How can we improve  dasatinib results in  newly diagnosed  Ph+ ALL?

During the EHA2021 Virtual Congress, the ALL Hub spoke with Sabina Chiaretti, Sapienza University of Rome, Rome, IT....

Updated results from the D-ALBA trial of dasatinib plus blinatumomab in newly diagnosed adult Ph+ ALL

The outcomes of patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia...

What are the main advances in patient care that we are seeing with novel agents for leukemia?

During the 2021 ASCO Annual Meeting, the ALL Hub spoke with Guru Subramanian Guru Murthy, Medical College...

COVID-19 vaccination for hematopoietic stem cell transplant patients

The SARS-CoV-2 pandemic has changed the world over the last year and impacted almost every part of our lives. In particular,...

What are the major challenges for CAR T-cell therapies in Europe during the COVID-19 pandemic?

During the Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation...

NCCN COVID-19 vaccination recommendations for patients with hematologic malignancies

Patients with cancer are at high risk of COVID-19-associated complications and, accordingly, the preliminary...

Use of ruxolitinib in patients with severe COVID-19

Colleagues from the RUXO-COVID Study Group have recently published the findings of a prospective observational study in Leukemia, in which they...

The role of Regnase-1 in CAR T-cell therapy: A potential target to improve responses in ALL

Treatment with chimeric antigen receptor (CAR) T cells is an effective treatment for B-cell acute...

How has targeted therapy impacted the prognosis for patients with a high disease burden in ALL?

During the European School of Haematology (ESH) 2nd Translational Research Conference: Acute...

Long-term data with CD19 CAR T-cell therapy in children and young adults with B-ALL

CD-19-directed chimeric antigen receptor (CAR) T-cell therapy has demonstrated highly encouraging results in...

Why should CAR T-cell therapy be used earlier in ALL?

During the Acute Leukemia Forum (ALF) 2021, the ALL Hub spoke to Stephan A. Grupp, Children’s Hospital of Philadelphia, Philadelphia, US. We...